Efficacy News and Research

RSS

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

20 May 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

Ring pessary for OAB as effective as nonsurgical therapies

The use of a ring pessary appears to be an effective, well tolerated and inexpensive treatment for overactive bladder, say US researchers writing in International Urogynecology Journal.

19 May 2014

CTR1 may be required for successful platinum-based therapy in NSCLC

Tumours with undetectable levels of the copper transporter CTR1 have a significantly reduced response to platinum-based chemotherapy for non-small-cell lung cancer, study findings indicate.

19 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

Study examines predictors and effects of testosterone therapy

Three new studies examining the predictors, effects and durability of testosterone therapy on men will be presented to reporters at the 109th Annual Scientific Meeting of the American Urological Association (AUA) during a special press conference in the Orange County Convention Center, Orlando, FL on Sunday, May 18 at 2:00 p.m. ET.

19 May 2014

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

Study shows technology improves transition into adulthood for adolescents with chronic disease

Adolescents with chronic diseases (ACD), such as cystic fibrosis, gastrointestinal disorders (including Crohn's disease) and Type 1 diabetes, often find the transition of managing their health care needs into adulthood to be challenging.

19 May 2014

IAVI: Together, we can achieve a world without AIDS

Do you remember the world before HIV/AIDS? Where will you be when the shadow of this disease is finally gone?

19 May 2014

Chronic bystander viral impairs development of memory T cells

Studies of vaccine programs in the developing world have revealed that individuals with chronic infections such as malaria and hepatitis tend to be less likely to develop the fullest possible immunity benefits from vaccines for unrelated illnesses.

16 May 2014

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).

16 May 2014

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),

16 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

16 May 2014

New intervention program may benefit chronically homeless, alcohol-dependent individuals

Chronically homeless, alcohol-dependent individuals might benefit from a new intervention that does not require them to stop or even reduce drinking, according to the results of a preliminary study in Seattle.

16 May 2014

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation.

16 May 2014

Corgenix announces that Randox received CE Mark notification for TxBCardio Assay

Corgenix Medical Corporation announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio™ Assay.

From Randox Laboratories Ltd. 15 May 2014

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Transition Therapeutics Inc. today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes.

15 May 2014

Efficacy News and Research

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Ring pessary for OAB as effective as nonsurgical therapies

CTR1 may be required for successful platinum-based therapy in NSCLC

Vandetanib delays disease progression in elderly NSCLC patients

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Study examines predictors and effects of testosterone therapy

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

Study shows technology improves transition into adulthood for adolescents with chronic disease

IAVI: Together, we can achieve a world without AIDS

Chronic bystander viral impairs development of memory T cells

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

New intervention program may benefit chronically homeless, alcohol-dependent individuals

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

Corgenix announces that Randox received CE Mark notification for TxBCardio Assay

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News